SYMBOL:

    Up to 100 tickers separated by a space .....Watch Post-Market activities
Site Map FAQ Contact us Home Personalize
Company
Industry
Earnings
US Markets
Most Active
Portfolio
Tools
ETFs
Ratings
SEATTLE GENETICS
(NQNM:SGEN Last Sale: 155.76 +0)
Fundamentals Charts Tech Analysis Industry Earnings
Company Profile   Details

Company Web Site
NQNM: (SGEN : $155.76)
$26,863,318 million Market Cap at Market Close, July 1, 2022
Employs 140.
Biomedics SubIndustry up .00% / Health Industry up .00% Today
21823 30th Drive SE Research Report Earnings Snapshot - Last 10/30/18
Bothell, WA 98021 Fact Sheet
Phone: (425) 489-4990 Financial Statements
Peer Comparison
Annual Reports

C.B. Siegall, Interim Chmn./CEO/Pres., Todd Simpson, CFO
Develops monoclonal antibody, or mAb, based drugs to treat cancer and related diseases. IPO at $7 March 6, 2001. Raised $49 million, selling 7 million shares, 24% of the outstanding. Lead Manager: J.P. Morgan. Incorporated in 1997. Secondary sold 7.3 million shares, raising $37.2 million, March 30, 2006.
Historical Charts    Technical Analysis
No Historical Data available for SGEN

Type of Stock Symbol Last Sale Last Close Net +/- % +/- Low High Volume 52wk Low 52wk High Shares(M)
Common SGEN $155.76 $155.76 0 .0 $145.01 $155.89 2,040,445 $145.01 $155.89 172,466,090
Capitalization
Earnings Summary ()
*** No Earnings Available***
-10126
Common Stock #############

A
Google



QUICK NAVIGATION SITE SEARCH   Enter Keyword:
   
Home    Subscribe    Browser Help    Subscriber Services    B-to-B    Banks    Brokerage    Telco    Site Map    Legal    Contact/Email
Copyright © 1996 - 2025 Stock Smart with all rights reserved
Feed is currently being brought back up
Provided by Nanex